R. Miceli

1.1k total citations
19 papers, 865 citations indexed

About

R. Miceli is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cellular and Molecular Neuroscience. According to data from OpenAlex, R. Miceli has authored 19 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in R. Miceli's work include Neuroscience and Neuropharmacology Research (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). R. Miceli is often cited by papers focused on Neuroscience and Neuropharmacology Research (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). R. Miceli collaborates with scholars based in United States, Netherlands and Italy. R. Miceli's co-authors include Tomás R. Guilarte, David A. Jett, N. L. Fox, Norma Lynn Fox, J P O'Callaghan, Anthony C Kuhlmann, S J Ullrich, A. W. Tolcher, George A. Fisher and Heather A. Wakelee and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

R. Miceli

19 papers receiving 849 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Miceli United States	14	485	187	172	165	126	19	865
Tianna Zhao United States	10	253 0.5×	73 0.4×	92 0.5×	140 0.8×	171 1.4×	14	835
Eric Van Buren United States	15	370 0.8×	57 0.3×	145 0.8×	65 0.4×	59 0.5×	33	809
Géraldine Pottier France	18	481 1.0×	45 0.2×	143 0.8×	69 0.4×	33 0.3×	30	945
Jared Iacovelli United States	19	713 1.5×	129 0.7×	65 0.4×	115 0.7×	39 0.3×	23	1.3k
Lorena Travaglini Italy	21	1.2k 2.4×	87 0.5×	93 0.5×	230 1.4×	34 0.3×	54	1.7k
Takaya Gotoh Japan	16	879 1.8×	152 0.8×	121 0.7×	118 0.7×	6 0.0×	30	1.3k
Wiesława Leśniak Poland	20	800 1.6×	199 1.1×	90 0.5×	91 0.6×	11 0.1×	46	1.0k
Ryoji Fujiki Japan	18	1.1k 2.3×	226 1.2×	111 0.6×	48 0.3×	19 0.2×	37	1.5k
Yi-Fen Lee United States	16	397 0.8×	68 0.4×	91 0.5×	176 1.1×	15 0.1×	20	740
Ján Strnádel Slovakia	17	543 1.1×	57 0.3×	141 0.8×	35 0.2×	28 0.2×	46	907

Countries citing papers authored by R. Miceli

Since Specialization

Citations

This map shows the geographic impact of R. Miceli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Miceli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Miceli more than expected).

Fields of papers citing papers by R. Miceli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Miceli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Miceli. The network helps show where R. Miceli may publish in the future.

Co-authorship network of co-authors of R. Miceli

This figure shows the co-authorship network connecting the top 25 collaborators of R. Miceli. A scholar is included among the top collaborators of R. Miceli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Miceli. R. Miceli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Lobmaier, Ingvild, Marta Spreafico, R. Miceli, et al.. (2025). A comparison of the risk prediction models PERSARC and Sarculator in patients with localized soft tissue sarcoma of the extremities and trunk wall. ESMO Open. 10(8). 105517–105517. 1 indexed citations

Miceli, R.. (2014). Molecular Mechanisms of Podocyte Development Revealed by Zebrafish Kidney Research. PubMed. 3(2). 19 indexed citations

Younes, Anas, Julie M. Vose, Andrew D. Zelenetz, et al.. (2010). A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. British Journal of Cancer. 103(12). 1783–1787. 112 indexed citations

Procopio, Giuseppe, Elena Verzoni, Sergio Bracarda, et al.. (2010). Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 28(15_suppl). 4589–4589. 3 indexed citations

Mom, Constantijne H., Jaap Verweij, Corina N.A.M. Oldenhuis, et al.. (2009). Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. Clinical Cancer Research. 15(17). 5584–5590. 85 indexed citations

Wakelee, Heather A., Amita Patnaik, Branimir I. Šikić, et al.. (2009). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Annals of Oncology. 21(2). 376–381. 120 indexed citations

Leong, Stephen, Roger B. Cohen, Daniel L. Gustafson, et al.. (2009). Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study. Journal of Clinical Oncology. 27(26). 4413–4421. 98 indexed citations

Procopio, Giuseppe, Elena Verzoni, Sergio Bracarda, et al.. (2009). 7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial. European Journal of Cancer Supplements. 7(2). 425–425. 3 indexed citations

Procopio, Giuseppe, Elena Verzoni, Sergio Bracarda, et al.. (2009). A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. Journal of Clinical Oncology. 27(15_suppl). 5099–5099. 3 indexed citations

10.

Riccobene, Todd, et al.. (2003). Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.. PubMed. 44(3). 422–33. 20 indexed citations

11.

Parry, Tom J., Todd Riccobene, Steven J. Strawn, et al.. (2001). Pharmacokinetics and Immunological Effects of Exogenously Administered Recombinant Human B Lymphocyte Stimulator (BLyS) in Mice. Journal of Pharmacology and Experimental Therapeutics. 296(2). 396–404. 38 indexed citations

12.

Han, Dong Soo, Fengling Li, Lisa Holt, et al.. (2000). Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. American Journal of Physiology-Gastrointestinal and Liver Physiology. 279(5). G1011–G1022. 67 indexed citations

13.

Miceli, R., et al.. (1999). Efficacy of Keratinocyte Growth Factor-2 in Dextran Sulfate Sodium-Induced Murine Colitis. Journal of Pharmacology and Experimental Therapeutics. 290(1). 464–471. 40 indexed citations

14.

Guilarte, Tomás R., R. Miceli, & David A. Jett. (1995). Biochemical evidence of an interaction of lead at the zinc allosteric sites of the NMDA receptor complex: effects of neuronal development.. PubMed. 16(1). 63–71. 51 indexed citations

15.

Guilarte, Tomás R., Anthony C Kuhlmann, J P O'Callaghan, & R. Miceli. (1995). Enhanced expression of peripheral benzodiazepine receptors in trimethyltin-exposed rat brain: a biomarker of neurotoxicity.. PubMed. 16(3). 441–50. 55 indexed citations

16.

Guilarte, Tomás R., R. Miceli, & David A. Jett. (1994). Neurochemical aspects of hippocampal and cortical Pb2+ neurotoxicity.. PubMed. 15(3). 459–66. 38 indexed citations

17.

Guilarte, Tomás R., R. Miceli, Lilo Altmann, et al.. (1993). Chronic prenatal and postnatal Pb2+ exposure increases [3H]MK801 binding sites in adult rat forebrain. European Journal of Pharmacology Environmental Toxicology and Pharmacology. 248(3). 273–275. 26 indexed citations

18.

Guilarte, Tomás R. & R. Miceli. (1992). Age-dependent effects of lead on [3H]MK-801 binding to the NMDA receptor-gated ionophore: in vitro and in vivo studies. Neuroscience Letters. 148(1-2). 27–30. 79 indexed citations

19.

Guilarte, Tomás R., R. Miceli, & Timothy H. Moran. (1991). Developmental effects of vitamin B-6 restriction on the locomotor behavior of rats. Brain Research Bulletin. 26(6). 857–861. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact